On January 11, 2017, Subsidiaries of Shire PLC, a multinational pharmaceutical firm headquartered in Ireland, agreed to pay $350 million to settle federal and state False Claims Act allegations.  The allegations were that Shire and Advanced BioHealing (“ABH”), which Shire acquired in 2011, paid kickbacks in order to induce clinics and physicians to use a product for the treatment of diabetic foot ulcers called “Dermagraft.”  The kickbacks were alleged to be in a variety of forms such as entertainment, travel, unwarranted payments for speaking engagements and medical equipment and supplies.  The settlement also resolved allegations that Shire and ABH unlawfully marketed, made false statements about, and caused improper coding, verification, or certification of Dermagraft.  The settlement originated out of six qui tam lawsuits brought pursuant to the whistleblower provisions of the False Claims Act. DOJ Press Release